Beta Bionics (NASDAQ:BBNX) Director Christy Jones Sells 1,998 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 1,998 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $9.95, for a total value of $19,880.10. Following the completion of the transaction, the director owned 13,246 shares of the company’s stock, valued at $131,797.70. The trade was a 13.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beta Bionics Stock Down 0.8%

Shares of NASDAQ:BBNX opened at $11.72 on Wednesday. The firm has a market cap of $522.24 million, a P/E ratio of -7.76 and a beta of 3.29. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The business has a fifty day simple moving average of $10.65 and a 200 day simple moving average of $17.93.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. The business had revenue of $27.63 million during the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. As a group, equities research analysts expect that Beta Bionics, Inc. will post -2.19 EPS for the current year.

Institutional Investors Weigh In On Beta Bionics

A number of hedge funds have recently modified their holdings of the stock. Eventide Asset Management LLC raised its holdings in shares of Beta Bionics by 0.8% in the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after purchasing an additional 37,476 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after purchasing an additional 110,000 shares during the period. Soleus Capital Management L.P. raised its holdings in shares of Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after purchasing an additional 424,817 shares during the period. Vanguard Group Inc. raised its holdings in shares of Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after purchasing an additional 1,509,217 shares during the period. Finally, Eversept Partners LP grew its stake in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. The Goldman Sachs Group lowered their target price on Beta Bionics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Stifel Nicolaus lowered their target price on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. UBS Group raised Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Leerink Partners decreased their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Finally, Weiss Ratings downgraded Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.